ClinicalTrials.gg
RecruitingNCT07546331Updated Apr 22, 2026

Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction

An observational study in Breast Carcinoma and Breast Cancer, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University of California, San Francisco · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Breast Neoplasms by University of California, San Francisco — 11 open to participants now, 16 under way, 1 of them phase 3. Breast Neoplasms · University of California, San Francisco.

Planned enrollment
9th of 12
40 · median 79
Started
2026
with 3 others
Observational
12 of 62
5 open now
Primary completion
2028-12
later than 8 of 15 live
Registered
61st of 62
by date

Among the 62 studies in Breast Neoplasms by University of California, San Francisco, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2026, is one of 12 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 61st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 62 studies in Breast Neoplasms by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Breast Neoplasms by University of California, San Francisco, or all of them as a file.
02

Study summary

This study compares measurements of body composition to outcomes of breast reconstruction.

Read the detailed description

PRIMARY OBJECTIVES:

1. Determine feasibility of collecting measurements of body composition.

SECONDARY OBJECTIVES:

  1. Define the differences in body composition between participants undergoing breast reconstruction who develop complications and those who do not.
  2. To determine the implications of different measures of body composition on outcomes of breast reconstruction.
  3. Compare utility of body composition measurements versus other anthropometric assessments on assessing risk of complications following breast surgery.

OUTLINE: This is a observational study. Participants are assigned to 1 of 2 cohorts and will be follow-up for up to 2 years.

03

Conditions studied

  • Breast Carcinoma
  • Breast Cancer

Browse trials for

Keywords

  • Postmastectomy breast reconstruction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants seen at University California of San Francisco (UCSF) clinics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed breast or increased risk of developing a breast malignancy.
  2. Age ≥ 18 years.
  3. Scheduled to undergo mastectomy with immediate breast reconstruction using a permanent implant, tissue expander, or autologous tissue (e.g. Deep Inferior Epigastric Perforator (DIEP) flap, muscle-sparing Transverse Rectus Abdominis Myocutaneous (msTRAM) flap, Profunda Artery Perforator (PAP) flap).
  4. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. Any significant medical condition or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  2. Pregnant or breastfeeding.
  3. Patients assigned male at birth.
  4. Non-cisgender women.
  5. Patients with implanted electronic medical devices (e.g. pacemaker, defibrillator).
  6. Patients with prosthetic limbs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort A: Implant-based Reconstruction

    Patients undergo standard of care implant-based breast reconstruction and body composition measurement on study.

    Procedure: Measurement of Body Composition · Other: Chart Review

  • Cohort B: Autologous Reconstruction

    Patients undergo standard of care autologous breast reconstruction and body composition measurement on study.

    Procedure: Measurement of Body Composition · Other: Chart Review

Interventions

  • ProcedureMeasurement of Body Composition

    Body composition measurements collected pre and post operatively using a bioelectrical impedance analyzer.

  • OtherChart Review

    Clinical and surgical data will be collected from the participants medical records.

06

What researchers measure

Primary outcomes

  1. Proportion of Body Composition Measurement Collection

    The proportion of enrolled participants with successfully obtained body composition measurements at both preoperative and postoperative timepoints. A success rate of ≥90% will be considered feasible. The proportion of the participants meets feasibility will be reported.

    Time frame: up to 2 years

Secondary outcomes

  1. Postoperative Variability of Body Composition

    To investigate how body fat measurements change after surgery and how consistent these measurements are when repeated.

    Time frame: up to 2 years

  2. Pre- to Postoperative Changes in Body Composition and Their Association with BMI

    Associations between body fat parameters and changes in BMI will be evaluated using correlative analyses.

    Time frame: up to 2 years

  3. Association Between Body Composition Parameters and Postoperative Complications Following Breast Reconstruction

    The association between body composition parameters and postoperative complications following breast reconstruction will be examined. Complications of interest include infection, seroma, hematoma, delayed wound healing, and tissue necrosis.

    Time frame: up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 34 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 22, 2026
StartActual
Feb 18, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07546331
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Feb 18, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Michael Choi
Contact
Michael.Choi@ucsf.edu
877-827-3222
Merisas Piper, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion